ANTIDEPRESSANT LIKE EFFECT OF NEWLY SYNTHESIZED COMPOUND 2[(N- BENZYLACETAMIDO) MERCAPTO] BENZIMIDAZOLE (VS 25) AND ITS POSSIBLE MECHANISM BY INHIBITION OF MONOAMINE OXIDASE ENZYME IN MICE
Objective: The objective of the study was to investigate the antidepressant activity of a newly synthesized compound 2 [(N-benzylacetamido) mercapto] benzimidazole (VS 25) by forced swimming test in mouse and to explore the mechanism of action by its effect on monoamine oxidase enzyme in mouse brain.
Methods: Swiss albino mice were randomly divided into 4 groups, each containing 6 animals. Group one was controlled and received 1 % cmc, p. o., Group II received moclobemide (50 mg/kg) p. o., group three and four received VS25 (30mg/kg and 60 mg/kg) once a day for 14 days.
Results: In the forced swim test the decrease in immobility was 38.10% in moclobemide treated mice compared to 34.66% in VS25 (30 mg/kg) and 28.77% in VS 25 (60 mg/kg) treated mice. The percentage inhibition of the monoamine oxidase enzyme in mouse brain mitochondria was in moclobemide treated animals was 75.19% compared to 66.94% in VS 25 (30mg/kg) and 55.52% in VS 25 (60 mg/kg) treated animals. Moclobemide did not inhibit MAO B enzyme while VS25 (30 mg/kg) showed 6.48% and VS 25 (60 mg/kg) showed 4.75% inhibition.
Conclusion: It is concluded that both moclobemide (50 mg/kg) and VS25 (30 mg/kg) showed antidepressant activity in mice. Moclobemide selectively inhibited MAO A enzyme in mouse brain. VS 25 (30 mg/kg) was equipotent as MAO A inhibitor but differed from moclobemide with respect to weak inhibition of MAO B activity also.
2. Lipson S, Chad E, Beyer, Zoe A, Hughes, Kawaka X, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113:134-53.
3. McKinney WT. Animal models of depression: an overview. Psychiatry 1984;2:77-96.
4. Willner P. Validity, reliability and utility of chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacol 1997;134:319-29.
5. Luo L. Antidepressant effects of banxia houpu decoction, a traditional Chinese medicinal empirical formula. J Ethnopharmacol 2000;73:277â€“81.
6. Chen KX. Quantitative structureâ€“activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities. Eur J Med Chem 2009;44:4367â€“75.
7. Baker GB, Matveychuk D, MacKenzie EM, Dursun SM, Mousseau DD. Monoamine oxidase inhibitors and neuroprotective mechanisms. Bull Clin Psychopharmacol 2012;22:293-6.
8. Shelke SM, Bhosale SH, Das RC, Suryawanshi MR, Mahadik K. Exploration of new scaffolds as potent MAO-A inhibitors using pharmacophore and 3D-QSAR based in silico screening. Bioorg Med Chem Lett 2011:21:2419-24.
9. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379-91.
10. Porsolt RD, Bertin A, Balavet N, Deniel M, Jalfre M. Immobility induced by forced swimming rats: effect of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979;57:201-10.
11. Abel EL, Bilitzke PJ. A possible alarm substance in the forced swimming test. Physiol Behav 1990;48:233-9.
12. Dhingra D, Goyal PK. Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of Tinospora cordifolia in mice. Indian J Pharm Sci 2008;70:761.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
14. Bowers SL, Bilbo SD, Dhabhar FS, Nelson RJ. Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immune 2008;22:105-13.
15. Cryan JF, Markou A, Irwin L. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-45.
16. Iversen L. The Monoamine Hypothesis of Depression. In: Licinio J, Wong ML, editors. Biology of Depression. From Novel Insights to Therapeutic Strategies. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim; 2005. p. 71-86.
17. Manji HK, Quiroz JA, Sporn J. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003;53:707â€“42.
18. Koelle GB, Valk Ade T. Physiological implications of the histochemical localization of monoamine oxidase. J Physiol 1954;126:434-47.
19. Davison AN. Physiological role of monoamine oxidase. Physiol Rev 1958;38:729-47.
20. Krajl Michael. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 1965;14:1684-5.
21. Snyder SH, Hendley ED. A simple and sensitive fluorescence assay for monoamine oxidase and diamine oxidase. J Pharmacol Exp Ther 1968;163:386-92.
22. Wurtman RJ, Axelrod J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharm 1963;12:1439-40.
23. Sweetman AJ, Weetman DF. Polarographic assay of monoamine oxidase. Br J Pharmacol 1969;37:550.
24. Weissbach H, Smith TE, Daly JW, Witkop B, Udenfriend SA. Rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J Biol Chem 1960:235:1160-3.
25. Robert F, Cerza MD. Beta-selective monoamine oxidase inhibitors and cardiac anesthesia. J Cardiothorac Vasc Anesth 1995;9:717-9.
26. Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 2002;83:161-5.
27. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002;36:124â€“38.